Patients With Sleep Apnea Have Increased Gout Risk

January 04, 2019

Among OSA patients, risk for developing gout is highest one to two years after the index date

Consensus Statement Issued on Management of Foot, Ankle Gout

November 15, 2018

Risk for gouty flares increased with use of thiazide diuretics, excessive alcohol intake

Failure to Meet Optimal Urate Levels Increases Mortality Risk in Gout

October 26, 2018

Patients with gout who did not reach a serum uric acid level below 6 mg/dL had a 2.4-fold increased risk for death.

Allopurinol Linked to Reduced Risk for CKD Stage ≥3 in Gout

October 25, 2018

Compared with non-users, allopurinol use ≥300mg/day was correlated with a lower risk for developing chronic kidney disease stage ≥3.

Allopurinol Dose Escalation for Gout Does Not Improve Mortality

September 20, 2018

There was an increase in all-cause mortality among dose escalators (hazard ratio, 1.08; 95% confidence interval, 1.01 to 1.17). Similar effect sizes were seen for incidence of cardiovascular-related deaths (hazard ratio, 1.08; 95% confidence interval, 0.97 to 1.21) and cancer-related deaths (hazard ratio, 1.06; 95% confidence interval, 0.88 to 1.27).

Quarterly Canakinumab Reduces Risk for Gout Attacks

September 19, 2018

"These data have relevance for the development of agents for gout that target the interleukin-1β pathway of innate immunity," the authors write.

Both High and Low Uric Acid Levels Tied to Higher Mortality

July 19, 2018

The researchers found that over the study period (2,060,721.9 person-years), 2020 participants died, with 287 cardiovascular disease (CVD)-related deaths and 963 cancer deaths. Both low and high uric acid levels were associated with increased all-cause, CVD, and cancer mortality.

Pegloticase Retreatment Effective for Gout After Gap in Therapy

By May 24, 2018

The study authors retrospectively analyzed the charts of 4 chronic gout patients from a practice-based rheumatology clinic.

Febuxostat Linked to Increased Death Risk in Gout Patients With Heart Disease

March 12, 2018

Participants were followed for a median of 32 months.

FDA: Gout Drug Linked to Increased Risk of Heart-Related Death

By November 15, 2017

The FDA required the Uloric drug manufacturer, Takeda Pharmaceuticals, to conduct this safety study when the medicine was approved in 2009.

Duzallo Now Available for the Treatment of Uncontrolled Gout

By October 10, 2017

The fixed-dose product combines lesinurad, a uric acid transporter 1 (URAT1) inhibitor, with allopurinol, a xanthine oxidase inhibitor in one tablet.

Uloric Dosing Updated to Include Patients with Severe Renal Impairment

By September 27, 2017

The new labeling now recommends patients with severe renal impairment be limited to a dose of 40mg once daily.

Fixed-Dose Combo Tx Duzallo Approved for Uncontrolled Gout

By August 21, 2017

This fixed-dose combination product combines lesinurad, a uric acid transporter 1 (URAT1) inhibitor, with allopurinol, a xanthine oxidase inhibitor in one tablet.

Drug Combo Effective for Tophaceous Gout

By June 09, 2017

When lesinurad 400mg was added to febuxostat, significantly more patients achieved target sUA by Month 6 (76.1%; P<0.0001) vs. febuxostat alone (46.8%); however, this was not seen with adding lesinurad 200mg (56.6%; P=0.13).

Recall: CV Meds Found to Contain Gout Pills

By May 26, 2017

Accidental patient dosing with Zurampic can potentially cause adverse renal effects such as acute renal failure; this is more common if Zurampic is given alone without a xanthine oxidase inhibitor.

Do Uric Acid Lowering Drugs Reduce BP in Hypertensive Patients?

By April 14, 2017

In general, there was low quality evidence from three trials indicating no reduction in systolic (-6.2mmHg, 95% CI: -12.8 to 0.5) or diastolic (-3.9mmHg, 95% CI: -9.2 to 1.4) 24-hour ambulatory BP with uric acid lowering drugs vs. placebo.

Dual-Mechanism Gout Treatment Under FDA Review

By January 04, 2017

The Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for Duzallo (lesinurad/allopurinol fixed-dose combination; Ironwood) for the treatment of hyperuricemia in patients with uncontrolled gout.

Review Finds Gout Therapy Monitoring 'Suboptimal' Among Veterans

By December 07, 2016

A retrospective chart review found that rates of urate-lowering therapy monitoring among United States veterans with gout were less than optimal. The full findings are published in the Annals of Pharmacotherapy.

Effects of DASH Diet on Serum Uric Acid Levels Explored

December 05, 2016

Greatest decrease in those with hyperuricemia; increasing sodium intake linked to drop in serum UA

Allopurinol Skin Reactions in Gout Might Predict Febuxostat Reactions

By November 14, 2016

Use of febuxostat (FBX) might cause skin reactions in some patients with gout who have experienced such reactions after allopurinol administration.

Review Looks at Effective Treatments for Gout Management

By November 02, 2016

A treatment review for acute gout attacks and management has found strong evidence that colchicine, NSAIDs, and corticosteroids are effective in relieving pain in acute gout patients.

New Oral Treatment for Uncontrolled Gout Available

By October 03, 2016

Zurampic is now available for combination use with a xanthine oxidase inhibitor for the treatment of hyperuricemia associated with gout in patients who have not achieved target serum uric acid levels with a xanthine oxidase inhibitor alone.

Can Lesinurad Added to Allopurinol Lower Serum Urate in Gout Patients?

By August 31, 2016

Adding lesinurad to allopurinol provided extra benefit vs. allopurinol alone in lower serum urate (sUA) levels and is an option for patients requiring additional urate-lowering, a study published in Arthritis & Rheumatology reported.

DASH Diet May Benefit Gout Patients

By August 15, 2016

A study published in Arthritis & Rheumatology has found that the DASH diet reduced serum uric acid, particularly in patients with hyperuricemia.

Gout Flares With Arhalofenate Vs Allopurinol Examined in Study

August 15, 2016

Arhalofenate (800mg) is safe and significantly decreases gout flares compared to allopurinol (300mg), according to a study published online July 27 in Arthritis & Rheumatology.

Gout Management Updates Reflect New Treatments

July 26, 2016

The European League Against Rheumatism (EULAR) have updated their recommendations on the management of gout to reflect novel treatments and evidence surrounding already established treatments.

Higher Allopurinol Dose May be Nephroprotective in Elderly

By June 17, 2016

A higher allopurinol dose provided a protective effect against incident renal failure in elderly patients, according to a study published in Annals of the Rheumatic Diseases.

Case: Post-Op Gouty Arthritis Secondary to HCTZ Use

April 19, 2016

A case of postoperative acute gouty arthritis following laparoscopic cholecystectomy with umbilical hernioplasty, secondary to hydrochlorothiazide use.

Gene Variant Linked to Severe Cutaneous Reactions with Gout Treatment

By April 14, 2016

Findings from a new study published in Seminars in Arthritis and Rheumatism show significant racial disparities in the risk of gout patients developing a serious, sometimes fatal adverse reaction to urate-lowering drugs.

REMS Requirement Removed for Gout Drug

By April 13, 2016

The Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for Krystexxa (pegloticase; Horizon) Injection.